Breast Cancers Today shared a post on LinkedIn:
“New findings from the phase 3 neoCARHP trial show that carboplatin can be safely omitted from neoadjuvant therapy for early-stage HER2‑positive breast cancer. Patients receiving THP achieved noninferior pCR rates with notably lower toxicity compared with TCbHP, highlighting a potentially safer, equally effective treatment option.
Read more. The findings were published in JCO Journals.”
Title: Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
Authors: Hong-Fei Gao, Guo-Lin Ye, Ying Lin, Qin Huang, Jie Dong, Yin Cao, Yan-Xia Zhao, Qian-Jun Chen, Shi-Hui Ma, Jie Ouyang, Jin-Hui Ye, Hua-Wei Yang, Yuan-Qi Zhang, Yong-Cheng Zhang, Gang-Ling Zhang, Wei Li, Yunjian Zhang, Zhi-Yong Wu, Ying-Yi Lin, Teng Zhu, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Hao Peng, Bo Chen, Yi-Tian Chen, Fei Ji, Min-Yi Cheng, Jie-Qing Li, Zefei Jiang, Kun Wang
Read The Full Article
Other articles about Breast Cancer on OncoDaily.